153 related articles for article (PubMed ID: 18500265)
1. Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas.
Têtu B; Popa I; Bairati I; L'Esperance S; Bachvarova M; Plante M; Harel F; Bachvarov D
Mod Pathol; 2008 Aug; 21(8):1002-10. PubMed ID: 18500265
[TBL] [Abstract][Full Text] [Related]
2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
3. WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study.
Netinatsunthorn W; Hanprasertpong J; Dechsukhum C; Leetanaporn R; Geater A
BMC Cancer; 2006 Apr; 6():90. PubMed ID: 16606472
[TBL] [Abstract][Full Text] [Related]
4. Identification of differentially expressed genes according to chemosensitivity in advanced ovarian serous adenocarcinomas: expression of GRIA2 predicts better survival.
Choi CH; Choi JJ; Park YA; Lee YY; Song SY; Sung CO; Song T; Kim MK; Kim TJ; Lee JW; Kim HJ; Bae DS; Kim BG
Br J Cancer; 2012 Jun; 107(1):91-9. PubMed ID: 22644307
[TBL] [Abstract][Full Text] [Related]
5. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation.
Choi YL; Kim J; Kwon MJ; Choi JS; Kim TJ; Bae DS; Koh SS; In YH; Park YW; Kim SH; Ahn G; Shin YK
Histol Histopathol; 2007 Nov; 22(11):1185-95. PubMed ID: 17647191
[TBL] [Abstract][Full Text] [Related]
6. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
[TBL] [Abstract][Full Text] [Related]
7. Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma.
Nymoen DA; Hetland Falkenthal TE; Holth A; Ow GS; Ivshina AV; Tropé CG; Kuznetsov VA; Staff AC; Davidson B
Gynecol Oncol; 2015 Oct; 139(1):30-9. PubMed ID: 26232338
[TBL] [Abstract][Full Text] [Related]
8. Poor survival with wild-type TP53 ovarian cancer?
Wong KK; Izaguirre DI; Kwan SY; King ER; Deavers MT; Sood AK; Mok SC; Gershenson DM
Gynecol Oncol; 2013 Sep; 130(3):565-9. PubMed ID: 23800698
[TBL] [Abstract][Full Text] [Related]
9. Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival.
Brenne K; Nymoen DA; Hetland TE; Trope' CG; Davidson B
Hum Pathol; 2012 Apr; 43(4):496-505. PubMed ID: 21855111
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary.
Choi CH; Sung CO; Kim HJ; Lee YY; Song SY; Song T; Kim J; Kim TJ; Lee JW; Bae DS; Kim BG
Hum Pathol; 2013 Jun; 44(6):1017-23. PubMed ID: 23290009
[TBL] [Abstract][Full Text] [Related]
11. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma.
Jung SG; Kwon YD; Song JA; Back MJ; Lee SY; Lee C; Hwang YY; An HJ
Cancer Sci; 2010 Sep; 101(9):1977-83. PubMed ID: 20624166
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract][Full Text] [Related]
14. Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis.
Espinosa I; Catasus L; Canet B; D'Angelo E; Muñoz J; Prat J
Mod Pathol; 2011 Jun; 24(6):846-54. PubMed ID: 21317880
[TBL] [Abstract][Full Text] [Related]
15. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
[TBL] [Abstract][Full Text] [Related]
16. Elevated expression of astrocyte elevated gene-1 (AEG-1) is correlated with cisplatin-based chemoresistance and shortened outcome in patients with stages III-IV serous ovarian carcinoma.
Li C; Li Y; Wang X; Wang Z; Cai J; Wang L; Zhao Y; Song H; Meng X; Ning X; Xu C; Lin M; Li L; Geng J
Histopathology; 2012 May; 60(6):953-63. PubMed ID: 22372608
[TBL] [Abstract][Full Text] [Related]
17. Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma.
Vaksman O; Hetland TE; Trope' CG; Reich R; Davidson B
Hum Pathol; 2012 Nov; 43(11):2062-9. PubMed ID: 22647351
[TBL] [Abstract][Full Text] [Related]
18. Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion.
Davidson B; Smith Y; Nesland JM; Kærn J; Reich R; Tropè CG
Hum Pathol; 2013 Nov; 44(11):2449-60. PubMed ID: 24011953
[TBL] [Abstract][Full Text] [Related]
19. Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma.
Kim YS; Hwan JD; Bae S; Bae DH; Shick WA
BMC Cancer; 2010 Oct; 10():576. PubMed ID: 20969748
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of Apaf-1, Cyclin D1, and AQP-5 in serous ovarian carcinoma treated with the first-line chemotherapy.
Abdelrahman AE; Fathy A; Elsebai EA; Nawar N; Etman WM
Ann Diagn Pathol; 2018 Aug; 35():27-37. PubMed ID: 30072015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
